Ivana Vranic, MD

Pfizer, United Kingdom

Poster(s):

• (005) Challenges, Lessons Learned and Implications for Improvement in Employing Drug Utilization Studies to Evaluate the Effectiveness of Additional Risk Minimization Measures (aRMMs)
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (035) Safety Events in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis Exposed to Tofacitinib (Xeljanz) or Biologics: Real-World Data from the CARRA Registry
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST